Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Queensland Health
Cantor Fitzgerald
Harvard Business School
Mallinckrodt

Generated: September 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,517,220

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,517,220 protect, and when does it expire?

Patent 9,517,220 protects PROLENSA and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 9,517,220
Title:Bromfenac bioavailability
Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY.TM. formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
Inventor(s): Padilla; Angel (Aliso Viejo, CA), Baklayan; George (Huntington Beach, CA)
Assignee: Bausch & Lomb Pharma Holdings Corp. (Rochester, NY)
Application Number:13/649,271
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,517,220
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,517,220

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb PROLENSA bromfenac sodium SOLUTION/DROPS;OPHTHALMIC 203168-001 Apr 5, 2013 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,517,220

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2852995   Try a Free Trial
European Patent Office 2765988   Try a Free Trial
Mexico 2014004347   Try a Free Trial
Mexico 348418   Try a Free Trial
World Intellectual Property Organization (WIPO) 2013055856   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
AstraZeneca
Julphar
Merck
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.